Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Hypoparathyroidism

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hypoparathyroidism

16 trials tracked for Hypoparathyroidism: 10 in phase 3 or 4 and 5 with published results. The most-cited published study has 77 citations.

16Trials tracked

10Phase 3 & 4

0Recruiting

5With published results

Phase distribution

Phase 4 3 Phase 3 7 Phase 2 3 Phase 1 2 Other / NA 1

Phase 4 A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism Completed · 77 cited
Phase 3 A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE) Completed · 67 cited
Phase 3 A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism Completed · 37 cited
Phase 3 HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism Completed · 8 cited
Phase 4 A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE) Completed · 4 cited
Phase 4 Does Treatment of Hypovitaminosis D Increase Calcium Absorption? Completed

Show 10 more trials

Phase 3 Use of NPSP558 in the Treatment of Hypoparathyroidism Completed
Phase 3 Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY) Completed
Phase 3 Bone Properties in Hypoparathyroidism: Effects of PTH Completed
Phase 3 A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary Completed
Phase 2 A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism Completed
Phase 2 Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism Completed
Phase 2 Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34 Completed
Phase 1 Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism Completed
Phase 1 Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects Completed
N/A Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy Completed

Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hypoparathyroidism: what the trials found

Several recombinant human parathyroid hormone (rhPTH) formulations have demonstrated efficacy in managing hypoparathyroidism symptoms and clinical markers. rhPTH(1-84) was associated with significant improvements in symptom scores, including the Hypoparathyroidism Symptom Diary (HypoPT-SD) and physical component summary scores ³, while also showing a 5.5% increase in bone mineral density (BMD) via DXA ⁷. Another PTH formulation showed a 2.9% to 0.95% change in BMD over 24 months ⁸.

TransCon PTH demonstrated significant improvements in physical and cognitive domain scores on the HPES scale compared to placebo ⁶, though its primary and secondary efficacy endpoints did not reach statistical significance in another trial ¹². Additionally, NPSP558 was associated with significant reductions in required oral calcium and active vitamin D dosages over time [5, 11].

Placebo groups showed significantly lower rates of meeting triple efficacy endpoints compared to treatment groups, which also demonstrated a significant reduction in daily calcium requirements and an increased proportion of patients achieving independence from high-dose vitamin D and oral calcium ⁹.

One study on NPSP558 at 8 weeks did not show a statistically significant difference in the primary triple endpoint between groups ¹⁰.

Recent results — preliminary, needs further review

Synthetic Human Parathyroid Hormone 1-34 was shown to significantly increase mean serum calcium levels in children and young adults (p=0.02) compared to baseline, while no significant change was observed in the adult cohort (p=0.41) ¹.
The PTeye imaging technique did not result in a statistically significant difference in the number of parathyroid glands identified or post-operative PTH levels when compared to naked eye observation alone ¹⁶.

For the clinician treating this condition

rhPTH(1-84) and TransCon PTH are associated with improved physical, cognitive, and symptom scores in patients with hypoparathyroidism.
Treatment with NPSP558 or other rhPTH formulations can significantly reduce the required dosage of oral calcium and vitamin D supplements.
Specific PTH interventions have demonstrated measurable increases in bone mineral density (BMD).
Synthetic Human Parathyroid Hormone 1-34 showed significant serum calcium increases specifically in pediatric and young adult populations.

AI synthesis of 9 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.